FDA Approves ACTOPLUS MET — Takeda Pharmaceuticals America, Inc.

Following Takeda Pharmaceuticals’ expansion into the thyroid disease market, the company was granted FDA approval on August 29, 2005, for Actoplus Met (pioglitazone and metformin HCl), a groundbreaking oral therapy for type 2 diabetes management. This approval set a pivotal precedent favoring fixed-dose combination regimens, positioning Takeda at the forefront of a rapidly evolving sector of the pharmaceutical landscape.